まとめ
ベラパミルは,カルシウムチャネルブロッカーであり,ベータアドレネルゲン受容体と相互作用し,その機能に影響を与えます. 人間に長期にわたってヴェラパミルを投与すると,ベータ受容体の活性が変化し,血のノルエピネフリン濃度が低下します.
科学分野:
- 薬理学 薬理学とは
- 心血管科学の研究について
- 細胞生物学 細胞生物学
背景:
- カルシウムチャネルブロッカー (CCB) は,心血管疾患に広く使用されています.
- CCBsとアドレネルゲン受容体の相互作用は完全に理解されていません.
- ベータアドレネルゲン受容体は,心血管の調節に重要な役割を果たします.
研究 の 目的:
- ベラパミル,ディルチアゼム,ニフェディピンがベータアドレナリン受容体に及ぼす影響を調査する.
- これらの相互作用がアデニラートサイクラース活性に及ぼす機能的影響を決定する.
- ベラパミルのベータ受容体機能とカテキオラミンレベルに対するインビボ効果を評価する.
主な方法:
- ラジオリガンド結合アッセイは,in vitroで受容体相互作用を研究するために使用されました.
- 機能的影響を評価するためにアデニラートサイクラース活性が測定されました.
- In vivo試験では,正常な被験者にヴェラパミルを投与し,リンパ球と血の分析を行った.
主要な成果:
- ベラパミルはベータ2アドレナリン受容体 (Ki = 32 microM) に対して有意な親和性を示したが,ディルチアゼムとニフェディピンはより強力ではなかった.
- 活性代謝産物であるノルベラパミルは,より高い afinity (Ki = 4.2 microM) を示した.
- In vivoでは,ヴェラパミルの治療により,イソプロテレノール刺激によるアデニラートサイクラース活性とβ受容体アゴニストの親和性が増加し,血のノルエピネフリン濃度が低下しました.
結論:
- ベラパミルは,リンパ球ベータ受容体とインビトロで相互作用する.
- ヴェラパミルの長期投与は,ヒトにおけるβ受容体の機能を調節する.
- これらの効果は,直接または間接的に,血カテキオラミンを減少させることで媒介されることがあります.
さらに関連する動画
関連する概念動画
Adrenergic Receptors (Adrenoceptors): Classification
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: β Subtype
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...


